- call +1-201-465-4211
- email sales@mrinsights.biz
According to this latest study, the 2021 growth of Non-alcoholic Steatohepatitis (NASH) Biomarkers will have significant change from previous year. By the most conservative estimates of global Non-alcoholic Steatohepatitis (NASH) Biomarkers market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the Non-alcoholic Steatohepatitis (NASH) Biomarkers market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-alcoholic Steatohepatitis (NASH) Biomarkers market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Serum Biomarkers
Cytokeratin-18 (CK 18) Marker
Inflammatory Markers
Others
Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Hospitals
Diagnostic Centers
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Biopredictive
Quest Diagnostics
Exalenz Bioscience
GENFIT
Siemens Healthineers
ONE WAY LIVER
Prometheus Laboratories
Gilead Sciences
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Consumption 2016-2026
2.1.2 Non-alcoholic Steatohepatitis (NASH) Biomarkers Consumption CAGR by Region
2.2 Non-alcoholic Steatohepatitis (NASH) Biomarkers Segment by Type
2.2.1 Serum Biomarkers
2.2.2 Cytokeratin-18 (CK 18) Marker
2.2.3 Inflammatory Markers
2.2.4 Others
2.3 Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Type
2.3.1 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Type (2016-2021)
2.3.2 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue and Market Share by Type (2016-2021)
2.3.3 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sale Price by Type (2016-2021)
2.4 Non-alcoholic Steatohepatitis (NASH) Biomarkers Segment by Application
2.4.1 Hospitals
2.4.2 Diagnostic Centers
2.4.3 Others
2.5 Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Application
2.5.1 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sale Market Share by Application (2016-2021)
2.5.2 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue and Market Share by Application (2016-2021)
2.5.3 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sale Price by Application (2016-2021)
3 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers by Company
3.1 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Company
3.1.1 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Company (2019-2021)
3.1.2 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Company (2019-2021)
3.2 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Company
3.2.1 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Company (2019-2021)
3.2.2 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Company (2019-2021)
3.3 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sale Price by Company
3.4 Global Manufacturers Non-alcoholic Steatohepatitis (NASH) Biomarkers Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Location Distribution
3.4.2 Players Non-alcoholic Steatohepatitis (NASH) Biomarkers Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Non-alcoholic Steatohepatitis (NASH) Biomarkers by Region
4.1 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers by Region
4.1.1 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Region
4.1.2 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Region
4.2 Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Growth
4.3 APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Growth
4.4 Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Growth
4.5 Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Growth
5 Americas
5.1 Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Country
5.1.1 Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Country (2016-2021)
5.1.2 Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Country (2016-2021)
5.2 Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Type
5.3 Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Region
6.1.1 APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Region (2016-2021)
6.1.2 APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Region (2016-2021)
6.2 APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Type
6.3 APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers by Country
7.1.1 Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Country (2016-2021)
7.1.2 Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Country (2016-2021)
7.2 Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Type
7.3 Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers by Country
8.1.1 Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Country (2016-2021)
8.1.2 Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Country (2016-2021)
8.2 Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Type
8.3 Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Non-alcoholic Steatohepatitis (NASH) Biomarkers Distributors
10.3 Non-alcoholic Steatohepatitis (NASH) Biomarkers Customer
11 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast
11.1 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Forecast by Region
11.1.1 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Forecast by Regions (2021-2026)
11.2.2 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Country
11.3 APAC Forecast by Region
11.4 Europe Forecast by Country
11.5 Middle East & Africa Forecast by Country
11.6 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Forecast by Type
11.7 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Forecast by Application
12 Key Players Analysis
12.1 Biopredictive
12.1.1 Biopredictive Company Information
12.1.2 Biopredictive Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
12.1.3 Biopredictive Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Biopredictive Main Business Overview
12.1.5 Biopredictive Latest Developments
12.2 Quest Diagnostics
12.2.1 Quest Diagnostics Company Information
12.2.2 Quest Diagnostics Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
12.2.3 Quest Diagnostics Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Quest Diagnostics Main Business Overview
12.2.5 Quest Diagnostics Latest Developments
12.3 Exalenz Bioscience
12.3.1 Exalenz Bioscience Company Information
12.3.2 Exalenz Bioscience Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
12.3.3 Exalenz Bioscience Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Exalenz Bioscience Main Business Overview
12.3.5 Exalenz Bioscience Latest Developments
12.4 GENFIT
12.4.1 GENFIT Company Information
12.4.2 GENFIT Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
12.4.3 GENFIT Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 GENFIT Main Business Overview
12.4.5 GENFIT Latest Developments
12.5 Siemens Healthineers
12.5.1 Siemens Healthineers Company Information
12.5.2 Siemens Healthineers Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
12.5.3 Siemens Healthineers Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Siemens Healthineers Main Business Overview
12.5.5 Siemens Healthineers Latest Developments
12.6 ONE WAY LIVER
12.6.1 ONE WAY LIVER Company Information
12.6.2 ONE WAY LIVER Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
12.6.3 ONE WAY LIVER Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 ONE WAY LIVER Main Business Overview
12.6.5 ONE WAY LIVER Latest Developments
12.7 Prometheus Laboratories
12.7.1 Prometheus Laboratories Company Information
12.7.2 Prometheus Laboratories Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
12.7.3 Prometheus Laboratories Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Prometheus Laboratories Main Business Overview
12.7.5 Prometheus Laboratories Latest Developments
12.8 Gilead Sciences
12.8.1 Gilead Sciences Company Information
12.8.2 Gilead Sciences Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
12.8.3 Gilead Sciences Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales, Revenue, Price and Gross Margin (2019-2021)
12.8.4 Gilead Sciences Main Business Overview
12.8.5 Gilead Sciences Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Non-alcoholic Steatohepatitis (NASH) Biomarkers Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Serum Biomarkers
Table 3. Major Players of Cytokeratin-18 (CK 18) Marker
Table 4. Major Players of Inflammatory Markers
Table 5. Major Players of Others
Table 6. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Type (2016-2021) & (K Units)
Table 7. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Type (2016-2021)
Table 8. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Type (2016-2021) & ($ million)
Table 9. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Type (2016-2021)
Table 10. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sale Price by Type (2016-2021)
Table 11. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Application (2016-2021) & (K Units)
Table 12. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Application (2016-2021)
Table 13. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Value by Application (2016-2021)
Table 14. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Application (2016-2021)
Table 15. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sale Price by Application (2016-2021)
Table 16. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Company (2019-2021) & (K Units)
Table 17. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Company (2019-2021)
Table 18. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Company (2019-2021) ($ Millions)
Table 19. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Company (2019-2021)
Table 20. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sale Price by Company (2019-2021)
Table 21. Key Manufacturers Non-alcoholic Steatohepatitis (NASH) Biomarkers Producing Area Distribution and Sales Area
Table 22. Players Non-alcoholic Steatohepatitis (NASH) Biomarkers Products Offered
Table 23. Non-alcoholic Steatohepatitis (NASH) Biomarkers Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Region (2016-2021) (K Units)
Table 27. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Region (2016-2021)
Table 28. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Region (2016-2021) & ($ Millions)
Table 29. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Region (2016-2021)
Table 30. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Country (2016-2021) & (K Units)
Table 31. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Country (2016-2021)
Table 32. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Country (2016-2021) & ($ Millions)
Table 33. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Country (2016-2021)
Table 34. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Type (2016-2021) & (K Units)
Table 35. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Type (2016-2021)
Table 36. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Application (2016-2021) & (K Units)
Table 37. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Application (2016-2021)
Table 38. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Region (2016-2021) & (K Units)
Table 39. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Region (2016-2021)
Table 40. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Region (2016-2021) & ($ Millions)
Table 41. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Region (2016-2021)
Table 42. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Type (2016-2021) & (K Units)
Table 43. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Type (2016-2021)
Table 44. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Application (2016-2021) & (K Units)
Table 45. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Application (2016-2021)
Table 46. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Country (2016-2021) & (K Units)
Table 47. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Country (2016-2021)
Table 48. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Country (2016-2021) & ($ Millions)
Table 49. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Country (2016-2021)
Table 50. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Type (2016-2021) & (K Units)
Table 51. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Type (2016-2021)
Table 52. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Application (2016-2021) & (K Units)
Table 53. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Application (2016-2021)
Table 54. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Country (2016-2021) & (K Units)
Table 55. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Country (2016-2021)
Table 56. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue by Country (2016-2021) & ($ Millions)
Table 57. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Country (2016-2021)
Table 58. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Type (2016-2021) & (K Units)
Table 59. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Type (2016-2021)
Table 60. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Application (2016-2021) & (K Units)
Table 61. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Application (2016-2021)
Table 62. Key and Potential Regions of Non-alcoholic Steatohepatitis (NASH) Biomarkers
Table 63. Key Application and Potential Industries of Non-alcoholic Steatohepatitis (NASH) Biomarkers
Table 64. Key Challenges of Non-alcoholic Steatohepatitis (NASH) Biomarkers
Table 65. Key Trends of Non-alcoholic Steatohepatitis (NASH) Biomarkers
Table 66. Non-alcoholic Steatohepatitis (NASH) Biomarkers Distributors List
Table 67. Non-alcoholic Steatohepatitis (NASH) Biomarkers Customer List
Table 68. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Forecast by Region (2021-2026) & (K Units)
Table 69. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Consumption Market Forecast by Region
Table 70. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Forecast by Region (2021-2026) & ($ millions)
Table 71. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share Forecast by Region (2021-2026)
Table 72. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Forecast by Country (2021-2026) & (K Units)
Table 73. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Forecast by Country (2021-2026) & ($ millions)
Table 74. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Forecast by Region (2021-2026) & (K Units)
Table 75. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Forecast by Region (2021-2026) & ($ millions)
Table 76. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Forecast by Country (2021-2026) & (K Units)
Table 77. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Forecast by Country (2021-2026) & ($ millions)
Table 78. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Forecast by Country (2021-2026) & (K Units)
Table 79. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Forecast by Country (2021-2026) & ($ millions)
Table 80. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Forecast by Type (2021-2026) & (K Units)
Table 81. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share Forecast by Type (2021-2026)
Table 82. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 83. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share Forecast by Type (2021-2026)
Table 84. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Forecast by Application (2021-2026) & (K Units)
Table 85. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share Forecast by Application (2021-2026)
Table 86. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 87. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share Forecast by Application (2021-2026)
Table 88. Biopredictive Basic Information, Non-alcoholic Steatohepatitis (NASH) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 89. Biopredictive Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
Table 90. Biopredictive Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 91. Biopredictive Main Business
Table 92. Biopredictive Latest Developments
Table 93. Quest Diagnostics Basic Information, Non-alcoholic Steatohepatitis (NASH) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 94. Quest Diagnostics Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
Table 95. Quest Diagnostics Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 96. Quest Diagnostics Main Business
Table 97. Quest Diagnostics Latest Developments
Table 98. Exalenz Bioscience Basic Information, Non-alcoholic Steatohepatitis (NASH) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 99. Exalenz Bioscience Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
Table 100. Exalenz Bioscience Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 101. Exalenz Bioscience Main Business
Table 102. Exalenz Bioscience Latest Developments
Table 103. GENFIT Basic Information, Non-alcoholic Steatohepatitis (NASH) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 104. GENFIT Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
Table 105. GENFIT Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 106. GENFIT Main Business
Table 107. GENFIT Latest Developments
Table 108. Siemens Healthineers Basic Information, Non-alcoholic Steatohepatitis (NASH) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 109. Siemens Healthineers Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
Table 110. Siemens Healthineers Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 111. Siemens Healthineers Main Business
Table 112. Siemens Healthineers Latest Developments
Table 113. ONE WAY LIVER Basic Information, Non-alcoholic Steatohepatitis (NASH) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 114. ONE WAY LIVER Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
Table 115. ONE WAY LIVER Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 116. ONE WAY LIVER Main Business
Table 117. ONE WAY LIVER Latest Developments
Table 118. Prometheus Laboratories Basic Information, Non-alcoholic Steatohepatitis (NASH) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 119. Prometheus Laboratories Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
Table 120. Prometheus Laboratories Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 121. Prometheus Laboratories Main Business
Table 122. Prometheus Laboratories Latest Developments
Table 123. Gilead Sciences Basic Information, Non-alcoholic Steatohepatitis (NASH) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 124. Gilead Sciences Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Offered
Table 125. Gilead Sciences Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 126. Gilead Sciences Main Business
Table 127. Gilead Sciences Latest Developments
List of Figures
Figure 1. Picture of Non-alcoholic Steatohepatitis (NASH) Biomarkers
Figure 2. Non-alcoholic Steatohepatitis (NASH) Biomarkers Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Growth Rate 2016-2026 (K Units)
Figure 7. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Serum Biomarkers
Figure 10. Product Picture of Cytokeratin-18 (CK 18) Marker
Figure 11. Product Picture of Inflammatory Markers
Figure 12. Product Picture of Others
Figure 13. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Type in 2020
Figure 14. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Type (2016-2021)
Figure 15. Non-alcoholic Steatohepatitis (NASH) Biomarkers Consumed in Hospitals
Figure 16. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Hospitals (2016-2021) & (K Units)
Figure 17. Non-alcoholic Steatohepatitis (NASH) Biomarkers Consumed in Diagnostic Centers
Figure 18. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Diagnostic Centers (2016-2021) & (K Units)
Figure 19. Non-alcoholic Steatohepatitis (NASH) Biomarkers Consumed in Others
Figure 20. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Others (2016-2021) & (K Units)
Figure 21. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Application (2016-2021)
Figure 22. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Application in 2020
Figure 23. Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market by Company in 2020 ($ Million)
Figure 24. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Company in 2020
Figure 25. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Regions (2016-2021)
Figure 26. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Region in 2020
Figure 27. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales 2016-2021 (K Units)
Figure 28. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue 2016-2021 ($ Millions)
Figure 29. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales 2016-2021 (K Units)
Figure 30. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue 2016-2021 ($ Millions)
Figure 31. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales 2016-2021 (K Units)
Figure 32. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue 2016-2021 ($ Millions)
Figure 33. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales 2016-2021 (K Units)
Figure 34. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue 2016-2021 ($ Millions)
Figure 35. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Country in 2020
Figure 36. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Country in 2020
Figure 37. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Type in 2020
Figure 38. Americas Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Application in 2020
Figure 39. United States Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 40. Canada Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 41. Mexico Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 42. Brazil Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 43. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Region in 2020
Figure 44. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Regions in 2020
Figure 45. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Type in 2020
Figure 46. APAC Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Application in 2020
Figure 47. China Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 48. Japan Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 49. Korea Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 50. Southeast Asia Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 51. India Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 52. Australia Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 53. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Country in 2020
Figure 54. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Country in 2020
Figure 55. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Type in 2020
Figure 56. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Application in 2020
Figure 57. Germany Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 58. France Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 59. UK Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 60. Italy Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 61. Russia Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 62. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Country in 2020
Figure 63. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Market Share by Country in 2020
Figure 64. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Type in 2020
Figure 65. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Sales Market Share by Application in 2020
Figure 66. Egypt Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 67. South Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 68. Israel Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 69. Turkey Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 70. GCC Country Non-alcoholic Steatohepatitis (NASH) Biomarkers Revenue Growth 2016-2021 ($ Millions)
Figure 71. Channels of Distribution
Figure 72. Distributors Profiles
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
